NSE: LINCOLN · BSE: 531633 · ISIN INE405C01035
Lincoln Pharmaceuticals Limited stock analysis
Lincoln Pharmaceuticals Limited ranks #1414 in the TickerSutra evidence-ranked universe with a score of 53/100 and 95% data confidence. The latest captured fundamentals show ROCE of 16.3%, quarterly sales growth of 15.1% and quarterly profit growth of 30.9%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.01×
- Strong CFO/EBITDA of 1.08×
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- No calculated threshold risk in the current snapshot.
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹472cr | ₹96cr | ₹69cr | 20.0% |
| 2023 | ₹510cr | ₹90cr | ₹73cr | 18.0% |
| 2024 | ₹581cr | ₹100cr | ₹93cr | 17.0% |
| 2025 | ₹623cr | ₹102cr | ₹82cr | 16.0% |
| 2026 | ₹671cr | ₹98cr | ₹88cr | 15.0% |
| TTM | ₹694cr | ₹101cr | ₹96cr | 15.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
MANAGEMENT COMMENTARY
Signals from filed documents
Munjal Patel: See, we'll start once we -- we have already submitted 3 products. And once these approvals are clear, we can again push up to more products, and then we might get the product approval for those three products also. On the long-term revenue target, sir, INR1,000 crores, I think earlier, we guided for FY '28.
Also, the company has diversified and started investing more into the regulatory part of the product -- of the registration of the product. Lincoln Pharmaceuticals Limited February 18, 2026 Page 3 of 15 So we are now expanding the portfolio in the different regions also, where we are entering into some niche therapeutic index in domestic market also as well as in the international markets also, doing all the research
Second step is the Cepha block, which was about to commence -- has already commenced, and the revenue has started churning around in that one also. Still lot of regulatory has to come, but whatever we could start with and the regulatories we are waiting on that will add on to the value, but today we are doing about roughly around INR45 crores business, which we are targeting this year. So that would be something whic
We have applied it from two countries. So as fast as we can, we will be able to get back the approval, then we can go ahead with it, but since we had SRA approval from Canada, we are open to all the markets as of now. So there is no such kind of a business loss, which we are facing.
But we are not doing it, is just to safeguard the company as a whole wherein if I get a kind of business, wherein I can have an additional revenue, it is beneficiary for the investor also and the company also. So that is our key focus wherein the pricing and right now, the inorganic growth if we can get, that's what we are looking at or we will grow from scratch by building up a greenfield project. So the money sitti
MANAGEMENT PROMISE LEDGER
Quantified statements on the clock
“Munjal Patel: See, we'll start once we -- we have already submitted 3 products. And once these approvals are clear, we can again push up to more products, and then we might get the product approval for those three products also. On the long-term revenue target, sir, INR1,000 crores, I think earlier, we guided for FY '28.”
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…